×

Behind the Merck-Idenix deal

10:06 AM ET Mon, 9 June 2014

Merck is buying Idenix Pharmaceuticals for $3.85 billion in a deal that has already been approved by the boards of both companies, reports CNBC's Meg Tirrell.